67 withdrawn. 67 Phase 2, 12 Phase 1, 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 67 | Withdrawn 67 |
| Phase 1 | 12 | Withdrawn 12 |
| Phase 3 | 8 | Withdrawn 8 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2025-11-07 | 2025-11-10 | |
| Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Montelukast Oral Granules - Asthma; Status, Asthma in Children | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2025-09-01 | 2024-11-18 | |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy Belumosudil - Chronic Graft Versus Host Disease | Phase 2 | Withdrawn | Kadmon, a Sanofi Company | 2025-06-16 | 2026-02-12 | |
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy - Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-06-01 | 2024-05-17 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| Tiotropium Handihaler vs. Tiotropium Respimat in COPD tiotropium bromide inhalation powder (Spiriva HandiHaler), tiotropium bromide (Spiriva Respimat), Hyperpolarized 129XeMRI - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Withdrawn | Duke University | 2023-05-01 | 2023-06-15 | |
| The Multicenter Topic Trial Ivacaftor - Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2021-12-01 | 2022-01-27 | |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Evaluating Effects of Curcumin in Moderate to Severe Asthmatics Curcumin, Placebo - Asthma | Phase 2 | Withdrawn | Loma Linda University | 2021-09-01 | 2021-11-17 | |
| Efficacy of Magnesium Sulfate Bolus in Pediatric Patients With Bronchiolitis Magnesium Sulfate - Bronchiolitis, Viral | Phase 2 / Phase 3 | Withdrawn | University of Louisville | 2021-07-21 | 2026-05-11 | |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2020-09-01 | 2021-05-14 | |
| Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) Assigned Interventions - Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2020-06-30 | 2023-05-06 | |
| A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen AZD8154 nebulizer suspension, 20 mg/mL, Placebo - Asthma | Phase 2 | Withdrawn | AstraZeneca | 2020-02-06 | 2020-11-03 | |
| Anakinra as a Rescue Treatment for Allergic Inflammation Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen - Asthma, Allergic | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-12-16 | 2022-06-08 | |
| Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline - BPH, Nocturia | Phase 1 / Phase 2 | Withdrawn | Robert W. Alexander, MD, FICS | 2019-11-01 | 2021-01-12 | |
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. QAW039 - Asthma, Asthma, Bronchial | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2019-10-15 | 2020-05-14 | |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-08-09 | 2021-05-07 | |
| A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma GSK2245035, Placebo, FP-DPI - Asthma | Phase 2 | Withdrawn | GlaxoSmithKline | 2019-01-21 | 2018-10-16 | |
| Accessing Mobility Using Wearable Sensors Exercise - COPD, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Baylor College of Medicine | 2018-05-21 | 2025-08-27 |
Showing 20 of 67. Sign in to see all of them.
Asthma (41) · Pulmonary Disease, Chronic Obstructive (15) · Bronchiolitis Obliterans Syndrome (7) · Bronchiolitis (3) · Respiratory Sounds (2) · Brain Injuries, Traumatic (1) · Bronchial Diseases (1) · Bronchiolitis, Viral (1) · Bronchitis, Chronic (1) · Cardiovascular Diseases (1) · Dyspnea (1) · Emphysema (1) · Eosinophilia (1) · Graft vs Host Disease (1) · Heart Failure (1)
Lung Diseases (66) · Respiratory Tract Diseases (66) · Bronchial Diseases (51) · Immune System Diseases (48) · Hypersensitivity, Immediate (41) · Respiratory Hypersensitivity (41) · Hypersensitivity (40) · Pathological Conditions, Signs and Symptoms (22) · Pathologic Processes (18) · Chronic Disease (17) · Disease Attributes (17) · Bronchitis (12) · Bronchiolitis (8) · Bronchiolitis Obliterans (7)
Antigens, Dermatophagoides (3) · Interleukin 1 Receptor Antagonist Protein (3) · montelukast (3) · Albuterol (2) · Allergens (2) · Magnesium Sulfate (2) · Receptors, Interleukin-6 (2) · Sodium Chloride (2) · Tiotropium Bromide (2) · 2-hydroxy-N,N-dimethyl-3-(2-((1-(5-methylfuran-2-yl)propyl)amino)-3,4-dioxocyclobut-1-enylamino)benzamide (1) · 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole (1) · Adalimumab (1) · Aging (1) · Anesthesia, Local (1) · Beclomethasone (1)
Boehringer Ingelheim (4) · GlaxoSmithKline (4) · University of Chicago (3) · University of North Carolina, Chapel Hill (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Novartis Pharmaceuticals (2) · Syntara (2) · University of Louisville (2) · Abbott (1) · Acerus Pharmaceuticals Corporation (1) · Ageless Regenerative Institute (1) · AstraZeneca (1) · Baylor College of Medicine (1) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1)
United States (28) · Australia (2) · Canada (2) · France (2) · Germany (2) · Russia (2) · United Kingdom (2) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1)
Michelle Hernandez, MD (2) · Adam Wanner, MD (1) · Aldo T Iacono, MD (1) · Alexander V Averyanov, MD, PhD (1) · Atul Malhotra, MD (1) · Beverly Paperiello (1) · Bijan Najafi, PhD (1) · Blanca Camoretti-Mercado, Ph.D. (1) · Charles Fogarty, MD (1) · Charles S Cox, Jr., MD (1)
PMID 16407509, PMID 28639856, PMID 34404358
R01HL135235 (3), 2009 (2), 2008 (1), P30CA060553 (1), P30DK072482 (1), UG1CA242643 (1), UL1RR024999 (1)